Literature DB >> 11571317

Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD.

P J Neumann1, S S Araki, A Arcelus, A Longo, G Papadopoulos, K S Kosik, K M Kuntz, A Bhattacharjya.   

Abstract

OBJECTIVES: To estimate annual transition probabilities (i.e., the likelihood that a patient will move from one disease stage to another in a given time period) for AD progression. Transition probabilities are estimated by disease stages (mild, moderate, severe) and settings of care (community, nursing home), accounting for differences in age, gender, and behavioral symptoms as well as the length of time a patient has been in a disease stage.
METHODS: Using data from the Consortium to Establish a Registry for Alzheimer's Disease (CERAD), the authors employed a modified survival analysis to estimate stage-to-stage and stage-to-nursing home transition probabilities. To account for individual variability, a Cox proportional hazards model was fit to the CERAD data to estimate hazard ratios for gender, age (50 to 64, 65 to 74, and more than 75 years), and level of behavioral symptoms (low/high, according to responses to the Behavioral Rating Scale for Dementia) for each of the key stage-to-stage and stage-to-nursing home transitions.
RESULTS: The transition probabilities underscore the rapid progression of patients into more severe disease stages and into nursing homes and the differences among population subgroups. In general, male gender, age under 65, and high level of behavioral symptoms were associated with higher transition probabilities to more severe disease stages. Disease progression is roughly constant as a function of the time a patient has spent in a particular stage.
CONCLUSIONS: Transition probabilities provide a useful means of characterizing AD progression. Economic models of interventions for AD should consider the varied course of progression for different population subgroups, particularly those defined by high levels of behavioral symptoms.

Entities:  

Mesh:

Year:  2001        PMID: 11571317     DOI: 10.1212/wnl.57.6.957

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  43 in total

Review 1.  Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

Authors:  Peter Johannsen
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

3.  Estimation and validation of a multiattribute model of Alzheimer disease progression.

Authors:  Eric Stallard; Bruce Kinosian; Arthur S Zbrozek; Anatoliy I Yashin; Henry A Glick; Yaakov Stern
Journal:  Med Decis Making       Date:  2010 Nov-Dec       Impact factor: 2.583

4.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Colin Green; Joanna Picot; Emma Loveman; Andrea Takeda; Jo Kirby; Andrew Clegg
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.

Authors:  Stefan J Teipel; Michael Ewers; Veronika Reisig; Bernd Schweikert; Harald Hampel; Michael Happich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-04-01       Impact factor: 5.270

6.  Deep brain stimulation for Alzheimer disease: a decision and cost-effectiveness analysis.

Authors:  Keyvan Mirsaeedi-Farahani; C H Halpern; G H Baltuch; D A Wolk; S C Stein
Journal:  J Neurol       Date:  2015-03-06       Impact factor: 4.849

7.  Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States.

Authors:  Ron Brookmeyer; Nada Abdalla; Claudia H Kawas; María M Corrada
Journal:  Alzheimers Dement       Date:  2017-12-07       Impact factor: 21.566

8.  Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients.

Authors:  Janne Martikainen; Hannu Valtonen; Tuula Pirttilä
Journal:  Eur J Health Econ       Date:  2004-06

9.  A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Authors:  S Salloway; R Sperling; S Gilman; N C Fox; K Blennow; M Raskind; M Sabbagh; L S Honig; R Doody; C H van Dyck; R Mulnard; J Barakos; K M Gregg; E Liu; I Lieberburg; D Schenk; R Black; M Grundman
Journal:  Neurology       Date:  2009-11-18       Impact factor: 9.910

Review 10.  Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.

Authors:  Colin Green
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.